Clinical Trial Update: SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study of chidamide (SHR2554) for relapsed/refractory peripheral T-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | Phase 3 | Status: RECRUITING